Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase III trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A (‘CMT1A’) and benefits from orphan drug status in Europe and the United States. An international pivotal Phase III study of PXT3003 in CMT1A, the PREMIER trial, is currently ongoing. PXT864 has generated encouraging Phase II results in Alzheimer’s disease and will be advanced through partnerships. Both of Pharnext’s lead assets originated from the Pleotherapy™ R&D approach. Pharnext draws the attention of investors to the financial and other risk factors detailed in its financial reports. More information can be found at www.pharnext.com. Pharnext is listed on the Euronext Growth Stock Exchange in Paris.
Location: France, Ile-de-France, Paris
Employees: 11-50
Total raised: $112.89M
Founded date: 2007
Investors 1
| Date | Name | Website |
| - | IPF Partne... | ipfpartner... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 07.06.2021 | - | $98.78M | - |
| 09.02.2012 | - | $10.63M | - |
| 08.09.2011 | - | $3.48M | - |
Mentions in press and media 28
| Date | Title | Description |
| 05.08.2023 | Startup Showcase: “Pharnext: Pioneering Pleotherapy for Neurological Diseases” | Welcome to EUStartup.news’ Startup Showcase, where we spotlight companies that are truly making a difference. Today, we introduce you to Pharnext, an advanced clinical-stage biopharmaceutical company based in Issy-les-moulineaux, France. Ph... |
| 28.12.2022 | Pharnext Strengthens its Ties With Néovacs to Secure the Next Steps in its Development | Increase in the funding commitment of Néovacs to cover cash requirements through the topline results of the pivotal Phase III clinical study of the drug candidate PXT3003, the PREMIER trial, in development in Charcot-Marie-Tooth Disease Typ... |
| 28.12.2022 | Pharnext Strengthens its Ties With Néovacs to Secure the Next Steps in its Development | Increase in the funding commitment of Néovacs to cover cash requirements through the topline results of the pivotal Phase III clinical study of the drug candidate PXT3003, the PREMIER trial, in development in Charcot-Marie-Tooth Disease Typ... |
| 28.11.2022 | The Board of Directors of Pharnext Acknowledges the Resignation of Dr. David Horn SOLOMON from his Duties as Chief Executive Officer and Director of the Company | PARIS, FRANCE / ACCESSWIRE / November 28, 2022 / Pharnext SA (FR001400BV89 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high ... |
| 31.10.2022 | Pharnext Announces that Neovacs Has Set Up a Management Trust to Manage the Pharnext Securities Issued and the Rights and Obligations of Neovacs under the Financing Agreement Signed on September 30th | Neovacs is setting up a management trust (the "Trust"), with Equitis Gestion as trustee, of which it is both settlor and beneficiary, to manage its rights and obligations as well as the Pharnext securities issued respectively to N... |
| 31.10.2022 | Pharnext Announces that Neovacs Has Set Up a Management Trust to Manage the Pharnext Securities Issued and the Rights and Obligations of Neovacs under the Financing Agreement Signed on September 30th | Neovacs is setting up a management trust (the "Trust"), with Equitis Gestion as trustee, of which it is both settlor and beneficiary, to manage its rights and obligations as well as the Pharnext securities issued respectively to N... |
| 23.08.2022 | Pharnext Announces a €2.5m Loan Agreement with Néovacs | PARIS, FRANCE / ACCESSWIRE / August 23, 2022 / Pharnext SA (FR0011191287-ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unme... |
| 20.06.2022 | Pharnext Holds Shareholders Meeting and Appoints Dr. James Kuo to Renewed Board of Directors | Pharnext shareholders approve 2021 financial statements and key resolutions at Annual General Meeting Dr. James Kuo co-optation to the Board brings key strategic experience to Pharnext PARIS, FRANCE / ACCESSWIRE / June 20, 2022 / Pharnext S... |
| 30.05.2022 | Pharnext Announces On-Schedule Completion of Patient Enrollment in its Pivotal Phase III Trial of PXT3003, the PREMIER Trial, for the Treatment of Charcot-Marie-Tooth Disease Type 1A | PARIS, FRANCE / ACCESSWIRE / May 30 2022 / Pharnext SA (FR0011191287 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet ... |
| 18.10.2021 | Pharnext : Data from First Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A, the PLEO-CMT Trial, Published in the Orphanet Journal of Rare Diseases | Pharnext Pharnext: Data from First Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A, the PLEO-CMT Trial, Published in the Orphanet Journal of Rare Diseases 18-Oct-2021 / 18:00 CET/CEST Dissemination of a French Reg... |
Show more